Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD
Discount Links:
NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/
Use Code: ConquerAging At Checkout.
Continue reading “Vitamin B6: Did It Increase NAD? (Test Results)” »
Incapable of replicating on their own, viruses must hijack other organisms, like bacteria, to continue their existence. Little wonder, then, that bacteria had to develop ways to fight back.
Among them is CRISPR, a kind of an immune system that keeps DNA records of previous infections and then uses a protein called Cas to attack viruses that show up again. When Cas reaches a targeted virus, it cleaves the viral DNA, protecting the bacteria from infection.
Researchers have harnessed that targeted, DNA-snipping ability as a gene editing tool for all kinds of organisms. CRISPR can now be found in a variety of fields doing a variety of jobs, from helping to fight sickle cell and high cholesterol in humans to gene editing animals and crops. It’s proven to be an amazingly versatile tool.
American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication.
According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35 percent.
While these results do sound promising, the full data is not yet released, so there’s still a lot we don’t know.
Never heard of this fellow before but if you have a spare 50 minutes it’s a good listen. A summary of aging and what we might do about it with the goal (after about 26 minutes) of making an aging vaccine.
Lecture given by Dr. Ronjon Nag at “The Peter Wells Memorial Lecture 2023″ which took place in London on May 3rd, 2023.
https://events.theiet.org/events/the-peter-wells-memorial-lecture-2023/
The new version of the human genome could lead to better diagnostics and treatment of genetic diseases.
Great overview of progress in the field of oncolytic viruses. Take home message: it’s super important to develop viruses that not only attack tumors directly, but also stimulate immune strong responses against the cancer. #genetherapy #biotechnology
Cancer treatments known as oncolytic viruses are being tested in clinical trials, and one, T-VEC or Imlygic®, has been approved by the FDA. Research now suggests that these treatments work not only by infecting and killing tumor cells, but that they may also be a form of cancer immunotherapy.
The early detection and treatment of dementia such as Alzheimer’s is still one of the great challenges of modern medicine. It is already known that certain proteins in the cerebrospinal fluid can be used to diagnose Alzheimer’s disease. However, the current detection methods for such biomarkers by means of biochemical tests can only confirm and quantify the presence of such pathological proteins. No conclusions can be drawn about their original morphology of the proteins using biochemical assays, which holds information on disease stages.
However, such information if obtained directly in a label-free manner could allow conclusions to be drawn about the stage of the disease and evaluate the efficiency of a prescribed treatment. A team from the Transport at Nanoscale Interfaces Laboratory at Empa and the Department of Neurology at the Cantonal Hospital in St. Gallen has now used atomic force microscopy (AFM) to visualize the proteins that are indicative of Alzheimer’s disease under conditions that are as close to reality as possible. The researchers recently published their results in the journal Communications Biology.
With the new study, the researchers add another piece of the puzzle to their insights into Alzheimer’s development and diagnosis.
Researchers from Uppsala University have developed a method that helps immune cells exit from blood vessels into a tumor to kill cancer cells. The goal is to improve treatment of aggressive brain tumors. The study has been published in the journal Cancer Cell.
Glioblastoma is an aggressive brain tumor that lacks efficient treatment. This is in part due to the ability of the tumor to suppress or evade the body’s natural anti-cancer immune response. Immunotherapy, using checkpoint inhibitors, can reactivate the immune system against cancer. However, for this type of treatment to be effective, specific immune cells known as killer T cells must be present within the tumor.
Unfortunately, blood vessels in brain cancer are dysfunctional and act as a barrier, preventing killer T cells from reaching the tumor. As a result, this form of immunotherapy, which is effective against many forms of cancer, is ineffective against brain cancers.
Two cases of highly contagious, drug-resistant ringworm infections have been detected in New York City — the first such cases reported in the U.S., the Centers for Disease Control and Prevention reported Thursday.
The infection was first identified in a 47-year-old woman who had developed a bad case of ringworm, also known as tinea, while traveling in Bangladesh.
A rash had erupted across most of her body and typical antifungal creams did nothing to alleviate it.
The brain is assumed to be hypoactive during cardiac arrest. However, animal models of cardiac and respiratory arrest demonstrate a surge of gamma oscillations and functional connectivity. To investigate whether these preclinical findings translate to humans, we analyzed electroencephalogram and electrocardiogram signals in four comatose dying patients before and after the withdrawal of ventilatory support. Two of the four patients exhibited a rapid and marked surge of gamma power, surge of cross-frequency coupling of gamma waves with slower oscillations, and increased interhemispheric functional and directed connectivity in gamma bands. High-frequency oscillations paralleled the activation of beta/gamma cross-frequency coupling within the somatosensory cortices. Importantly, both patients displayed surges of functional and directed connectivity at multiple frequency bands within the posterior cortical “hot zone,” a region postulated to be critical for conscious processing. This gamma activity was stimulated by global hypoxia and surged further as cardiac conditions deteriorated in the dying patients. These data demonstrate that the surge of gamma power and connectivity observed in animal models of cardiac arrest can be observed in select patients during the process of dying.
